Home › NDC Lookup › RxCUI directory › RxCUI 1543004

Amylase 15125 UNT / lipase 4000 UNT / protease 14375 UNT Delayed Release Oral Capsule — RxCUI 1543004

RxNorm drug concept · Semantic clinical drug
RxCUI 1543004 Semantic clinical drug · SCD ● Current RxNorm concept 4 FDA products 14 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1543004
Official nameAmylase 15125 UNT / lipase 4000 UNT / protease 14375 UNT Delayed Release Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asamylase 15,125 UNT / lipase 4000 UNT / protease 14,375 UNT Delayed Release Oral Capsule; amylases 15,125 UNT / endopeptidases 14,375 UNT / lipase 4000 UNT Delayed Release Oral Capsule
FDA products mapped4
Package NDCs mapped14
Reported Medicaid activity (SDUD)3,229 prescriptions · 24 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

🕸️ Concept Web — How Amylase 15125 UNT / lipase 4000 UNT / protease 1... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Amylase 15125 UNT / lipase 4000 UNT / protease 14375 UNT Delayed Release Oral Capsule RxCUI 1543004

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 4

    The active substance itself — no strength, form, or brand attached yet.

    • Amylase 743
    • Lipase 6406
    • Protease 8031
    • Amylase / lipase / protease 392491
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Pertzye 1294123
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Amylase / lipase / protease Delayed Release Oral Capsule 402754
    • Amylase / lipase / protease Oral Product 1153486
    • Amylase / lipase / protease Pill 1153487
    • Amylase / lipase / protease Delayed Release Oral Capsule [Pertzye] 1294125
    • Pertzye Oral Product 1294126
    • Pertzye Pill 1294127
    • Delayed Release Oral Capsule 316995
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 5

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 18 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Amylase 15125 UNT SCDC · 1543002
  • Lipase 4000 UNT SCDC · 335940
  • Protease 14375 UNT SCDC · 1543003
  • Amylase / lipase / protease Delayed Release Oral Capsule SCDF · 402754
  • Amylase / lipase / protease Oral Product SCDG · 1153486
  • Amylase / lipase / protease Pill SCDG · 1153487

Brand-Name Concepts

📦 FDA Products & Package NDCs

4 products · 14 package NDCs
14 package NDCs map to RxCUI 1543004 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
59767-0004-01 100 CAPSULE, DELAYED RELEASE in 1 BOTTLE (59767-004-01) PERTZYE Digestive Care, Inc. 2016-10-06
59767-0004-99 100 CAPSULE, DELAYED RELEASE in 1 BOTTLE (59767-004-99) PERTZYE Digestive Care, Inc. 2016-10-06
59767-0008-00 20 CAPSULE, DELAYED RELEASE in 1 BOTTLE (59767-008-00) PERTZYE Digestive Care, Inc. 2014-01-23
59767-0008-01 100 CAPSULE, DELAYED RELEASE in 1 BOTTLE (59767-008-01) PERTZYE Digestive Care, Inc. 2012-05-17
59767-0008-02 250 CAPSULE, DELAYED RELEASE in 1 BOTTLE (59767-008-02) PERTZYE Digestive Care, Inc. 2012-05-17
59767-0008-99 100 CAPSULE, DELAYED RELEASE in 1 BOTTLE (59767-008-99) PERTZYE Digestive Care, Inc. 2012-05-17
59767-0016-00 20 CAPSULE, DELAYED RELEASE in 1 BOTTLE (59767-016-00) PERTZYE Digestive Care, Inc. 2014-01-23
59767-0016-01 100 CAPSULE, DELAYED RELEASE in 1 BOTTLE (59767-016-01) PERTZYE Digestive Care, Inc. 2012-05-17
59767-0016-02 250 CAPSULE, DELAYED RELEASE in 1 BOTTLE (59767-016-02) PERTZYE Digestive Care, Inc. 2012-05-17
59767-0016-99 100 CAPSULE, DELAYED RELEASE in 1 BOTTLE (59767-016-99) PERTZYE Digestive Care, Inc. 2012-05-17
59767-0024-00 20 CAPSULE, DELAYED RELEASE in 1 BOTTLE (59767-024-00) PERTZYE Digestive Care, Inc. 2017-07-13
59767-0024-01 80 CAPSULE, DELAYED RELEASE in 1 BOTTLE (59767-024-01) PERTZYE Digestive Care, Inc. 2017-07-13
59767-0024-02 200 CAPSULE, DELAYED RELEASE in 1 BOTTLE (59767-024-02) PERTZYE Digestive Care, Inc. 2017-07-13
59767-0024-99 80 CAPSULE, DELAYED RELEASE in 1 BOTTLE (59767-024-99) PERTZYE Digestive Care, Inc. 2017-07-13
Observed labelers: Digestive Care, Inc. (14) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.